Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: Phase I results of the SAKK 38/08 trial

Annals of Hematology

Volumn 92, Issue 8, 2013, Pages 1033-1040

  Hitz, F ^a   Fischer, N ^b   Pabst, Th ^c   Caspar, C ^d   Berthod, G ^e   Eckhardt, K ^f   Berardi Vilei, S ^f   Zucca, E ^g   Mey, U ^h  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d Cantonal Hospital Baden   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^g REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^h Kantonsspital Chur   (Switzerland)

Author keywords

Aggressive B cell lymphoma; Bendamustine; Elderly; Lenalidomide; Relapse; Rituximab

Indexed keywords

BENDAMUSTINE; LENALIDOMIDE; RITUXIMAB;

AGED; ANOREXIA; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHARLSON COMORBIDITY INDEX; COMORBIDITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SIDE EFFECT; SINUS TACHYCARDIA; THROMBOCYTOPENIA; URINARY TRACT INFECTION; WORLD HEALTH ORGANIZATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; FATIGUE; FEMALE; HEART DISEASES; HEMATOLOGIC DISEASES; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; NITROGEN MUSTARD COMPOUNDS; SALVAGE THERAPY; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84880259494     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1751-z     Document Type: Article

References (32)

1. Weisenburger DD (1994) Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic. Ann Oncol 5(Suppl 1):19-24
2. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107:265-276
3. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP Study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126
4. Gisselbrecht C, Glass B, Mounier N, Gill DS, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N (2010) Salvage regimens with autologous transplantation for relapsed large B cell lymphoma in the rituximab era. J Clin Oncol 28:4184-4190
5. van Spronsen DJ, Janssen-Heijnen MLG, Breed WPM, Coebergh JWW (1999) Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol 78:315-319
6. Thieblemont C, Grossoeuvre A, Houot R, Broussais-Guillaumont F, Salles G, Traulle C, Espinouse D, Coiffier B (2008) Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 19:774-779
7. van de Schans SAM, Wymenga ANM, van Spronsen DJ, Schouten HC, Coebergh JWW, Janssen-Heijnen MLG (2012) Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. Ann Oncol 23:1280-1286
8. Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 10:204-10
9. Kahl BS, Bartelett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Cancer 116:106-114
10. Rigacci L, Puccini B, Cortelazzo S, Gaidano G, Piccin A, D'Arco A, Freilone R, Storti S, Orciuolo E, Zinzani PL, Zaja F, Bongarzoni V, Balzarotti M, Rota-Scalabrini D, Patti C, Gobbi M, Carpaneto A, Liberati AM, Bosi A, Iannitto E (2012) Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients. Ann Hematol 91:1013-1022
11. Rummel M, Niederle N, Maschmeyer G, et al (2012) Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as a first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. J Clin Oncol 30: Abstract 3
12. Ogura M, Ando K, Taniwaki M, Watanabe T, Uchida T, Ohmachi K, Matsumoto Y, Tobinai K (2011) Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Cancer Sci 102(9):1687-92
13. Walter E, Schmitt T, Dietrich S, Ho A, Witzens-Harig M (2012) Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Leuk Lymphoma 53:2290-2
14. Horn J, Kleber M, Hieke S, Schmitt-Gräff A, Wäsch R, Engelhardt M (2012) Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance. Ann Hematol 91:1579-1586
15. Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, Jäger E (2011) Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 22:1839-44
16. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly Guo HP, Pietronigro D, Ervin-Haynes AL, Czuczman MS (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 22:1622-1627
17. Czuczman MS, Vose JM, Witzig TE, Zinzani PL, Buckstein R, Polikoff J, Li J, Pietronigro D, Ervin-Haynes A, Reeder CB (2011) The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. Br J Haematol 154:477-481
18. Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M (2011) Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 11:462-6
19. Balducci L, Extermann M (2000) Management of the frail person with advanced cancer. Crit Rev Oncol Hematol 33(2):143-8
20. WHO (2008) WHO classification of tumours of haematopoetic and lymphoid tissue, 4th edn. WHO, Geneva
21. Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S (2004) An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 20:4-94
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373-383
23. Kouroukis CT, Browman GP, Esmail R, Meyer RM (2002) Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma: a systematic review. Ann Intern Med 136:144-152
24. Fowler N, Hagemeister F, McLaughlin P, Kwak L, Romaguera J, Fanale M, Neelapu S, Fayad L, Orlowski L, Wang M, Pro B, Lacerte L, Samaniego F (2011) Lenalidomide plus rituximab is a highly effective and well-tolerated biologic therapy in untreated indolent B cell non-Hodgkin lymphoma. Ann of Oncol 22: Abstract 137
25. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis CB, Habermann TM (2008) Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 26(30):4952-7
26. Lentzsch S, O'Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL, Burt S, Boyiadzis M, Roodman GD, Mapara YM, Agha M, Waas J, Shuai Y, Normolle D, Zonder JA (2012) Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 119:4608-4613
27. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van Horn L, Tracy RP, Lloyd-Jones DM (2012) Lifetime risks of cardiovasculare disease. N Engl J Med 366:321-9
28. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L (1998) Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16:1582-1587
29. Extermann M (2000) Measuring comorbidity in older cancer patients. Eur J Cancer 36:453-471
30. Extermann M (2000) Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35:181-200
31. Mandelblatt JS, Bierman AS, Gold K, Zhang Y, Ng JH, Maserejan N, Hwang Y, Meropol NJ, Hadley J, Silliman RA (2001) Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methods. Health Serv Res 36:1085-1107
32. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329(14):987-94